The case against calcium-based phosphate binders.

Sharon Moe, Glenn M. Chertow

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Disturbances of mineral metabolism are associated with significant morbidity and mortality in patients with chronic kidney disease. Unfortunately, some of the treatments for these disturbances also have been found to be associated with morbidity. More recently, there is increasing evidence in the form of prospective, randomized trials that the use of calcium-based phosphate binders contributes to progressive coronary artery and aorta calcification compared with the non-calcium-containing binder sevelamer. Moreover, there is compelling biologic plausibility that hyperphosphatemia and excess exogenous calcium administration can accelerate vascular calcification. Unfortunately, there is no bedside test that can determine whether there is a dose of calcium salts (either as maintenance or as cumulative dose) that can be administered safely, and, unfortunately, the serum calcium concentration does not reflect calcium balance. Therefore, calcium-based phosphate binders should be avoided in many, if not most, patients who are undergoing dialysis.

Original languageEnglish
Pages (from-to)697-703
Number of pages7
JournalClinical Journal of the American Society of Nephrology
Volume1
Issue number4
DOIs
StatePublished - Jul 2006

Fingerprint

Calcium
Hyperphosphatemia
Morbidity
Vascular Calcification
Chronic Renal Insufficiency
Minerals
Aorta
Dialysis
Coronary Vessels
Salts
Maintenance
Mortality
calcium phosphate
Serum
Therapeutics
Sevelamer

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The case against calcium-based phosphate binders. / Moe, Sharon; Chertow, Glenn M.

In: Clinical Journal of the American Society of Nephrology, Vol. 1, No. 4, 07.2006, p. 697-703.

Research output: Contribution to journalArticle

@article{c95628af3b3e4ea1a4e0f169952691c6,
title = "The case against calcium-based phosphate binders.",
abstract = "Disturbances of mineral metabolism are associated with significant morbidity and mortality in patients with chronic kidney disease. Unfortunately, some of the treatments for these disturbances also have been found to be associated with morbidity. More recently, there is increasing evidence in the form of prospective, randomized trials that the use of calcium-based phosphate binders contributes to progressive coronary artery and aorta calcification compared with the non-calcium-containing binder sevelamer. Moreover, there is compelling biologic plausibility that hyperphosphatemia and excess exogenous calcium administration can accelerate vascular calcification. Unfortunately, there is no bedside test that can determine whether there is a dose of calcium salts (either as maintenance or as cumulative dose) that can be administered safely, and, unfortunately, the serum calcium concentration does not reflect calcium balance. Therefore, calcium-based phosphate binders should be avoided in many, if not most, patients who are undergoing dialysis.",
author = "Sharon Moe and Chertow, {Glenn M.}",
year = "2006",
month = "7",
doi = "10.2215/CJN.00560206",
language = "English",
volume = "1",
pages = "697--703",
journal = "Clinical journal of the American Society of Nephrology : CJASN",
issn = "1555-9041",
publisher = "American Society of Nephrology",
number = "4",

}

TY - JOUR

T1 - The case against calcium-based phosphate binders.

AU - Moe, Sharon

AU - Chertow, Glenn M.

PY - 2006/7

Y1 - 2006/7

N2 - Disturbances of mineral metabolism are associated with significant morbidity and mortality in patients with chronic kidney disease. Unfortunately, some of the treatments for these disturbances also have been found to be associated with morbidity. More recently, there is increasing evidence in the form of prospective, randomized trials that the use of calcium-based phosphate binders contributes to progressive coronary artery and aorta calcification compared with the non-calcium-containing binder sevelamer. Moreover, there is compelling biologic plausibility that hyperphosphatemia and excess exogenous calcium administration can accelerate vascular calcification. Unfortunately, there is no bedside test that can determine whether there is a dose of calcium salts (either as maintenance or as cumulative dose) that can be administered safely, and, unfortunately, the serum calcium concentration does not reflect calcium balance. Therefore, calcium-based phosphate binders should be avoided in many, if not most, patients who are undergoing dialysis.

AB - Disturbances of mineral metabolism are associated with significant morbidity and mortality in patients with chronic kidney disease. Unfortunately, some of the treatments for these disturbances also have been found to be associated with morbidity. More recently, there is increasing evidence in the form of prospective, randomized trials that the use of calcium-based phosphate binders contributes to progressive coronary artery and aorta calcification compared with the non-calcium-containing binder sevelamer. Moreover, there is compelling biologic plausibility that hyperphosphatemia and excess exogenous calcium administration can accelerate vascular calcification. Unfortunately, there is no bedside test that can determine whether there is a dose of calcium salts (either as maintenance or as cumulative dose) that can be administered safely, and, unfortunately, the serum calcium concentration does not reflect calcium balance. Therefore, calcium-based phosphate binders should be avoided in many, if not most, patients who are undergoing dialysis.

UR - http://www.scopus.com/inward/record.url?scp=34547121836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547121836&partnerID=8YFLogxK

U2 - 10.2215/CJN.00560206

DO - 10.2215/CJN.00560206

M3 - Article

C2 - 17699275

AN - SCOPUS:34547121836

VL - 1

SP - 697

EP - 703

JO - Clinical journal of the American Society of Nephrology : CJASN

JF - Clinical journal of the American Society of Nephrology : CJASN

SN - 1555-9041

IS - 4

ER -